About Reunion Neuroscience
Reunion Neuroscience is a company based in Toronto (Canada) founded in 2022 was acquired by MPM Capital in June 2023. Reunion Neuroscience has raised $103 million across 1 funding round from investors including Novo Holdings, Arkin Holdings and Mitsui Global Investment. Reunion Neuroscience offers products and services including RE104 and RE200s. Reunion Neuroscience operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Cerecor and Neurovance, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Reunion Neuroscience Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$103 M (USD)
in 1 rounds
-
Latest Funding Round
$103 M (USD), Series A
Jan 12, 2024
-
Investors
Novo Holdings
& 7 more
-
Employee Count
Not available
-
Acquired by
MPM Capital
(Jun 01, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Reunion Neuroscience
Reunion Neuroscience offers a comprehensive portfolio of products and services, including RE104 and RE200s.
Prodrug targeting serotonin receptors for treating mental health disorders.
Psilocybin-like compound for fast-acting mental health therapies.
People of Reunion Neuroscience
Unlock access to complete
Funding Insights of Reunion Neuroscience
Reunion Neuroscience has successfully raised a total of $103M through 1 strategic funding round. The most recent funding activity was a Series A round of $103 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Reunion Neuroscience
Reunion Neuroscience has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Novo Holdings, Arkin Holdings and Mitsui Global Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital firm focused on healthcare, IT, and multiple sectors
|
Locked | Locked | Locked |
Investor details for Reunion Neuroscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Reunion Neuroscience
Investment portfolio details for Reunion Neuroscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Reunion Neuroscience
Detailed financials for Reunion Neuroscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Reunion Neuroscience Comparisons
Peer comparison for Reunion Neuroscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Reunion Neuroscience
Reunion Neuroscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Cerecor and Neurovance, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for central nervous system diseases and pain are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
Detailed competitors of Reunion Neuroscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Reunion Neuroscience
Complete news archive for Reunion Neuroscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Reunion Neuroscience
Reunion Neuroscience was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Reunion Neuroscience is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Greg Mayes is the current CEO of Reunion Neuroscience.
Reunion Neuroscience is a funded company, having raised a total of $103M across 1 funding round to date.
Reunion Neuroscience was founded in 2022 in Toronto, Canada, within the biotechnology sector. Focus is placed on creating treatments for mental health disorders, including treatment-resistant depression and postpartum depression. The lead candidate, RE-104, is formulated as a serotonin-2A agonist prodrug. Additional efforts involve the RE-200 series of selective serotonergic psychedelic compounds. Operations center on research and development of these therapeutic options.
Reunion Neuroscience's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Reunion Neuroscience offers RE104 and RE200s.
Reunion Neuroscience has 8 investors. Key investors include Novo Holdings, Arkin Holdings, Mitsui Global Investment, Plaisance Capital, and FemHealth Ventures.